Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell

MT Newswires Live

2025/09/17

Astria Therapeutics (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.

Shares of the company were up more than 4% in recent Wednesday premarket activity.

The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.

STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.

Price: 7.60, Change: +0.33, Percent Change: +4.54

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568496342"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568496342\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568496342?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 20:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568496342","market":"sh","top_or_hot":-1,"title":"Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.</p><p>Shares of the company were up more than 4% in recent Wednesday premarket activity.</p><p>The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.</p><p>STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.</p><p>Price: 7.60, Change: +0.33, Percent Change: +4.54</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-17 20:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.</p><p>Shares of the company were up more than 4% in recent Wednesday premarket activity.</p><p>The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.</p><p>STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.</p><p>Price: 7.60, Change: +0.33, Percent Change: +4.54</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568496342","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568496342","pubTimestamp":1758112157,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Astria Therapeutics (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 we","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","ATXS":"Astria Therapeutics Inc","BK4539":"次新股","LENZ":"Therapeutics"},"translate_title":"Astria Therapeutics表示，STAR-0310在1a期试验中显示半衰期为68天；分享盘前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATXS":1},"content_text":"Astria Therapeutics (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.Shares of the company were up more than 4% in recent Wednesday premarket activity.The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.Price: 7.60, Change: +0.33, Percent Change: +4.54","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}